55790-22-2

Usage

InChI:InChI=1/C9H8INO3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5H2,(H,11,14)(H,12,13)

Upstream product

• 207864-22-0 N-(4-iodobenzoyl)glycine ethyl ester 
• 619-58-9 4-iodobenzoic acid 

Downstream Products

• 247140-20-1 4-iodo-N-{[{[2-(4-methoxy-phenyl)-ethylcarbamoyl]-methyl}-(phenethylcarbamoyl-methyl)-carbamoyl]-methyl}-benzamide 
• 207864-22-0 N-(4-iodobenzoyl)glycine ethyl ester 
• 1219614-16-0 2-(4-(trimethylstannyl)benzamido)acetic acid 
• 1219614-18-2 (S)-N-(2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl)-4-iodobenzamide 

Relevant academic research and scientific papers

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Facile synthesis of para-[18F]fluorohippurate via iodonium ylide-mediated radiofluorination for PET renography

para-[18F]fluorohippurate ([18F]PFH) is a renal tubular agent suitable for conducting positron emission tomography (PET) renography. [18F]PFH is currently synthesized by a four-step two-pot procedure utilizing a classical

POLYMER PRECURSORS OF RADIOLABELED COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME

One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.

Evaluation of the radiolabeled boronic acid-based FAP Inhibitor MIP-1232 for atherosclerotic plaque imaging

Research towards the non-invasive imaging of atherosclerotic plaques is of high clinical priority as early recognition of vulnerable plaques may reduce the incidence of cardiovascular events. The fibroblast activation protein alpha (FAP) was recently prop